Cargando…

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment

In the United States, approximately 25% of people with HIV (PWH) are co-infected with hepatitis C (HCV). Since 2014, highly effective and well-tolerated direct-acting antivirals (DAAs) have revolutionized HCV treatment. Uptake of DAAs by people with HIV/HCV co-infection has improved but remains subo...

Descripción completa

Detalles Bibliográficos
Autores principales: Brothers, Sarah, DiDomizio, Elizabeth, Nichols, Lisa, Brooks, Ralph, Villanueva, Merceditas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663279/
https://www.ncbi.nlm.nih.gov/pubmed/35776253
http://dx.doi.org/10.1007/s10461-022-03749-8
_version_ 1784830837457420288
author Brothers, Sarah
DiDomizio, Elizabeth
Nichols, Lisa
Brooks, Ralph
Villanueva, Merceditas
author_facet Brothers, Sarah
DiDomizio, Elizabeth
Nichols, Lisa
Brooks, Ralph
Villanueva, Merceditas
author_sort Brothers, Sarah
collection PubMed
description In the United States, approximately 25% of people with HIV (PWH) are co-infected with hepatitis C (HCV). Since 2014, highly effective and well-tolerated direct-acting antivirals (DAAs) have revolutionized HCV treatment. Uptake of DAAs by people with HIV/HCV co-infection has improved but remains suboptimal due to system, provider, and patient-level barriers. To explore patient-level issues by better understanding their attitudes towards DAA treatment, we conducted qualitative interviews with 21 persons with HIV/HCV co-infection who did not consent to DAA treatment or delayed treatment for at least 1 year after diagnosis. We found PWH perceived DAA treatment barriers and facilitators on multiple levels of the social-ecological environment: the individual (HCV disease and treatment literacy), interpersonal (peer influence), institutional (media and healthcare provider relationship), and structural levels (treatment cost and adherence support). Recommendations to improve DAA treatment uptake include HCV-treatment adherence support, HCV disease and treatment literacy training (particularly for substance use and DAA treatment interactions), and encouraging PWH who have successfully completed DAA treatment to speak with their peers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10461-022-03749-8.
format Online
Article
Text
id pubmed-9663279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96632792022-11-14 Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment Brothers, Sarah DiDomizio, Elizabeth Nichols, Lisa Brooks, Ralph Villanueva, Merceditas AIDS Behav Original Paper In the United States, approximately 25% of people with HIV (PWH) are co-infected with hepatitis C (HCV). Since 2014, highly effective and well-tolerated direct-acting antivirals (DAAs) have revolutionized HCV treatment. Uptake of DAAs by people with HIV/HCV co-infection has improved but remains suboptimal due to system, provider, and patient-level barriers. To explore patient-level issues by better understanding their attitudes towards DAA treatment, we conducted qualitative interviews with 21 persons with HIV/HCV co-infection who did not consent to DAA treatment or delayed treatment for at least 1 year after diagnosis. We found PWH perceived DAA treatment barriers and facilitators on multiple levels of the social-ecological environment: the individual (HCV disease and treatment literacy), interpersonal (peer influence), institutional (media and healthcare provider relationship), and structural levels (treatment cost and adherence support). Recommendations to improve DAA treatment uptake include HCV-treatment adherence support, HCV disease and treatment literacy training (particularly for substance use and DAA treatment interactions), and encouraging PWH who have successfully completed DAA treatment to speak with their peers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10461-022-03749-8. Springer US 2022-07-01 2023 /pmc/articles/PMC9663279/ /pubmed/35776253 http://dx.doi.org/10.1007/s10461-022-03749-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Brothers, Sarah
DiDomizio, Elizabeth
Nichols, Lisa
Brooks, Ralph
Villanueva, Merceditas
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
title Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
title_full Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
title_fullStr Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
title_full_unstemmed Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
title_short Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
title_sort perceptions towards hcv treatment with direct acting antivirals (daas): a qualitative analysis with persons with hiv/hcv co-infection who delay or refuse treatment
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663279/
https://www.ncbi.nlm.nih.gov/pubmed/35776253
http://dx.doi.org/10.1007/s10461-022-03749-8
work_keys_str_mv AT brotherssarah perceptionstowardshcvtreatmentwithdirectactingantiviralsdaasaqualitativeanalysiswithpersonswithhivhcvcoinfectionwhodelayorrefusetreatment
AT didomizioelizabeth perceptionstowardshcvtreatmentwithdirectactingantiviralsdaasaqualitativeanalysiswithpersonswithhivhcvcoinfectionwhodelayorrefusetreatment
AT nicholslisa perceptionstowardshcvtreatmentwithdirectactingantiviralsdaasaqualitativeanalysiswithpersonswithhivhcvcoinfectionwhodelayorrefusetreatment
AT brooksralph perceptionstowardshcvtreatmentwithdirectactingantiviralsdaasaqualitativeanalysiswithpersonswithhivhcvcoinfectionwhodelayorrefusetreatment
AT villanuevamerceditas perceptionstowardshcvtreatmentwithdirectactingantiviralsdaasaqualitativeanalysiswithpersonswithhivhcvcoinfectionwhodelayorrefusetreatment